Curis, Inc. (CRIS) News
Follow Curis, Inc. (CRIS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 23 public stories across 15 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Curis Receives Nasdaq Delisting Determination After Bid-Price Violation
Curis said it received a Nasdaq delisting determination after its stock closed below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The body is truncated after not
REGULATION | Nov 06, 2026, 09:33 PM UTC
L
CRIS: trading halted on Nasdaq — volatility pause (9:34 AM ET)
Nasdaq halted trading in CRIS (volatility pause) at 9:34 AM ET.
EQUITY | Nov 04, 2026, 02:50 PM UTC
M
Curis Shares Rise 83% in Premarket Trading
EQUITY | Nov 04, 2026, 12:23 PM UTC
M
Curis shares rise 42.18% to $1.02 in extended trading
EQUITY | Nov 03, 2026, 10:44 PM UTC
L
CRIS: trading halted on Nasdaq — volatility pause (12:49 PM ET)
Nasdaq halted trading in CRIS (volatility pause) at 12:49 PM ET.
EQUITY | Nov 03, 2026, 05:59 PM UTC
L
CRIS: trading halted on Nasdaq — volatility pause (12:11 PM ET)
Nasdaq halted trading in CRIS (volatility pause) at 12:11 PM ET.
EQUITY | Nov 03, 2026, 05:39 PM UTC
M
Curis Prices $8.5 Million Private Placement
Curis announced a $8.5 million private placement priced at-the-market under Nasdaq rules with existing healthcare-focused institutional investors.
EQUITY | Oct 16, 2026, 12:01 PM UTC
L
Curis, Inc. prices $5.6 million public offering
Curis, Inc. (CRIS) announces the pricing of a $5.6 million public offering.
MNA | Aug 13, 2026, 12:00 PM UTC
M
Multiple Companies Price Offerings
Several companies announce pricing of various offerings
EQUITY | Aug 11, 2026, 09:30 AM UTC
H
Curis Reaches Enrollment Milestone
Curis reaches enrollment milestone in CLL study
EQUITY | Jul 30, 2026, 12:11 PM UTC
H
Curis Doses First Patients in TakeAim CLL Study
Curis starts dosing in TakeAim CLL study
EQUITY | Jul 30, 2026, 12:01 PM UTC
H
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
On Wednesday, Curis Inc. (NASDAQ: CRIS ) announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance. The biotechnology firm detailed key advance
EARNINGS | Jul 24, 2026, 06:03 PM UTC
H
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates
Curis Inc. (NASDAQ: CRIS ) on Wednesday announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance. The biotechnology firm detailed key advances
EARNINGS | Jul 22, 2026, 05:04 PM UTC
L
Curis Consents 6 Patients in Phase 2 Trial of Emavusertib in Chronic Lymphocytic Leukemia
() -- Curis (CRIS) said Monday it has consented the first six patients in a phase 2 study of emavusertib in chronic lymphocytic leukemia, or CLL, just days after opening 11 clinical sites for enrollment. The biotechnolog
EQUITY | Jul 06, 2026, 02:11 PM UTC
H
Curis Announces It Has Consented The First Six Patients In The TakeAim CLL Study
On June 26, 2026, Curis announced that eleven clinical sites had opened for enrollment in the TakeAim CLL study. Today, Curis is announcing that it has consented the first six patients in that study – and reaffirmed its
EARNINGS | Jul 06, 2026, 01:33 PM UTC
L
Why Did Curis (CRIS) Stock Soar After Hours?
Curis, Inc. (NASDAQ: CRIS ) shares surged 8.51% to $0.46 after the bell on Wednesday, after the Massachusetts-based biotechnology company confirmed its previously approved reverse stock split will take effect on Thursday
EQUITY | Jul 02, 2026, 07:12 AM UTC
L
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ: CRIS ) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ: HUMA ) shares moved upwards by 5.45% to $0.71. The marke
EQUITY | Jul 01, 2026, 09:05 PM UTC
L
Curis shares are trading lower after the company announced that its stockholders have approved a 1‑for‑20 reverse split of its common stock.
Curis shares are trading lower after the company announced that its stockholders have approved a 1‑for‑20 reverse split of its common stock.
EQUITY | Jul 01, 2026, 06:02 PM UTC
L
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Can Fite Biopharma (AMEX: CANF ) shares rose 43.8% to $4.27 during Wednesday's regular session. The company's market cap stands at $6.3 million. Regencell Bioscience (NASDAQ: RGC ) stock moved upwards by 35.79% t
EQUITY | Jul 01, 2026, 05:05 PM UTC
H
Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket
Shares of Universe Pharmaceuticals Inc (NASDAQ: UPC ) rose sharply in pre-market trading after the company announced it will acquire Best Praise International for $10.75 million. Universe Pharmaceuticals shares jumped 22
RATES | Jun 29, 2026, 11:03 AM UTC
H
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers INVO Fertility (NASDAQ: IVF ) shares moved upwards by 67.3% to $2.08 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. The company's, Q1 earnings came out 4 days ag
EARNINGS | Jun 26, 2026, 05:05 PM UTC
M
CRIS: Expands Clinical Sites
Curis expands clinical sites in TakeAim CLL study and reaffirms patient dosing guidance
EARNINGS | Jun 26, 2026, 01:44 PM UTC
M
12 Health Care Stocks Move
Multiple health care stocks are moving in Thursday's intraday session, with gainers including Atlantic International and SELLAS Life Sciences, and losers including Nano X Imaging and Passage Bio
EQUITY | Jun 25, 2026, 05:05 PM UTC